checkAd

News, news, news (Seite 8)

eröffnet am 29.01.20 18:00:03 von
neuester Beitrag 08.04.21 19:47:09 von


Beitrag schreiben

Begriffe und/oder Benutzer

 

Fragen

 Ja Nein
Avatar
01.02.20 21:33:06
Ansonsten wäre die Sache ok denk ich mal
WPD Pharmaceuticals | 1,250 €
Avatar
02.02.20 22:34:21
Antwort auf Beitrag Nr.: 62.555.243 von Achim1967 am 01.02.20 21:33:06Denke das DKFZ spielt hier auch noch eine wichtige Rolle!
WPD Pharmaceuticals | 1,250 €
Avatar
03.02.20 07:18:02
Offizielle News nach Börsenschluss
Hier die original Meldung... Nix Pollinger WPD Pharmaceuticals Completed the Acquisition of Two Pancreatic Cancer Drug Candidates VANCOUVER, British Columbia, Jan. 31, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company, provides this update on the completed acquisition of exclusive sublicenses for two drug candidates from Moleculin Biotech, Inc. (Nasdaq: MBRX) a leading global pharmaceuticals company focused on the treatment of highly resistant cancers. The territory covered by the patents includes 30 countries in Europe and Asia, including Russia. The licensed drug candidates, WP1122 and WP1732, are both considered promising potential therapies for treating pancreatic cancer, among other highly resistant tumors. WP1732 appears capable of a disproportionately high accumulation in the pancreas, making it a promising candidate for treating pancreatic cancer. WP1122 is capable of inhibiting glycolysis, a process by which cells convert glucose into energy and one on which many tumor cells are known to be much more dependent for their survival than normal cells. In particular, pancreatic cancer is known to be highly dependent on glycolysis. The incidence of and number of deaths caused by pancreatic cancer have been gradually rising, even as the incidence and mortality of other common cancers have been declining. Removal of the pancreatic cancer tumor is currently the only chance of cure. Unfortunately, 80% to 85% of patients diagnosed with pancreatic cancer are at an advanced stage and the tumor has overtaken the pancreas and even surrounding tissues. Furthermore, pancreatic cancer responds poorly to most chemotherapeutic agents. Mariusz Olejniczak, CEO of WPD commented, “The Acquisition of these two pancreatic cancer drug candidates is an important step for WPD, and continues to demonstrate our ability to execute on our long term strategy of developing novel treatments for cancer. Working with some of the world’s leading cancer scientists, we are diligently focused on developing our portfolio of eight drugs across five different indications. We will continue working with Moleculin to further develop these drug candidates in our ongoing effort to create improved treatments for pancreatic cancer and other highly resistant tumors.” The Company also announces that on January 29, 2020 it granted 200,000 options to a new member of its scientific advisory board. The options are exercisable for 5 years at an exercise price of $1.23 per share. About WPD Pharmaceuticals WPD is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. WPD has 8 novel drug candidates with 4 that are in clinical development stage and 4 in pre-clinical development. These drug candidates were researched at institutions including MD Anderson Cancer Center, Mayo Clinic and Emory University, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland. WPD has entered into license agreements with Wake Forest University Health Sciences and sublicense agreements with Moleculin Biotech Inc. and CNS Pharmaceuticals, Inc., respectively, each of which grant WPD an exclusive, royalty-bearing sublicense to certain technologies of the licensor. Such agreements provide WPD with certain research, development, manufacturing and sales rights, among other things. On Behalf of the Board ‘Mariusz Olejniczak’ Mariusz Olejniczak CEO, WDP Pharmaceuticals Contact: Investor Relations Email: investors@wpdpharmaceuticals.com Tel: 604-428-7050 Web: www.wpdpharmaceuticals.com Cautionary Statements

News, news, news | wallstreet-online.de - Vollständige Diskussion unter:
https://www.wallstreet-online.de/diskussion/1319444-61-70/ne…
WPD Pharmaceuticals | 1,250 €
Avatar
03.02.20 08:01:26
Antwort auf Beitrag Nr.: 62.561.284 von NiewiederFerkel am 03.02.20 07:18:02Die Meldung ist von Freitag nach AH und ~20min später kam der Pollinger Pump, siehe News hier auf WO.
WPD Pharmaceuticals | 1,280 €
2 Antworten?Die Baumansicht ist in diesem Thread nicht möglich.
Avatar
03.02.20 08:46:43
Antwort auf Beitrag Nr.: 62.561.572 von gl_77 am 03.02.20 08:01:26
Bereich
hier einmal ein Input in welchem Bereich das Unternehmen und deren Partner agieren,

https://www.krebsinformationsdienst.de/service/iblatt/iblatt…
WPD Pharmaceuticals | 1,280 €
1 Antwort?Die Baumansicht ist in diesem Thread nicht möglich.
Avatar
03.02.20 11:12:42
Antwort auf Beitrag Nr.: 62.561.917 von gl_77 am 03.02.20 08:46:43Pollinger pumpt auf jede neue Nachricht,

Heute 09:05 Offizielle News
https://www.globenewswire.com/news-release/2020/02/03/197850…

Pollinger Pump eine Stunde später 10:02
https://www.wallstreet-online.de/nachricht/12124960-breaking…
WPD Pharmaceuticals | 1,350 €
Avatar
03.02.20 13:15:58
..... die haben sich also jetzt 100 Millionen Schulden
eingekauft !!
WPD Pharmaceuticals | 1,285 €
Avatar
03.02.20 13:16:24
Antwort auf Beitrag Nr.: 62.563.162 von gl_77 am 03.02.20 11:12:42@Pollinger ... nix neues in „deinem“ neuen Pump-Artikel ... ist das ALLES? Aneinandergereihte Wiederholungen!
WPD Pharmaceuticals | 1,285 €
Avatar
03.02.20 16:26:47
..........wer will da günstig rein...........
WPD Pharmaceuticals | 1,075 €
Avatar
03.02.20 16:45:25
Der Kurs versteht nun was Sache ist.... gute Nacht...Der letzte macht das Licht aus
WPD Pharmaceuticals | 1,085 €
 Durchsuchen


Beitrag zu dieser Diskussion schreiben

News, news, news